Chronic Δ9-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids

被引:23
|
作者
McMahon, Lance R. [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA
基金
美国国家卫生研究院;
关键词
cannabinoid; cross-tolerance; drug discrimination; efficacy; fixed ratio responding; rhesus monkey; tolerance; APPARENT PA(2) ANALYSIS; CENTRAL-NERVOUS-SYSTEM; DISCRIMINATIVE-STIMULUS; RAT-BRAIN; NONTOLERANT PIGEONS; SIGNAL-TRANSDUCTION; MORPHINE-TOLERANCE; RECEPTOR; DELTA(9)-TETRAHYDROCANNABINOL; AGONIST;
D O I
10.1111/j.1476-5381.2010.01116.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND AND PURPOSE The extent to which behavioural effects vary as a function of CB(1) receptor agonist efficacy is not clear. These studies tested the hypothesis that cannabinoid tolerance and cross-tolerance depend upon the CB(1) agonist efficacy of drugs to which tolerance/cross-tolerance develops. EXPERIMENTAL APPROACH Sensitivity to cannabinoids, including the cannabinoid antagonist rimonabant, low efficacy agonist Delta 9-tetrahydrocannabinol (Delta 9-THC), and high efficacy agonists CP 55940 and WIN 55212-2, was determined before and after chronic Delta 9-THC treatment in rhesus monkeys. Two measures of behavioural effect were assessed: effects of drugs to decrease fixed ratio responding for food presentation and stimulus-shock termination and discriminative stimulus effects in monkeys discriminating Delta 9-THC (0.1 mg center dot kg-1, i.v.). KEY RESULTS Delta 9-THC decreased responding for both food presentation and stimulus-shock termination; these effects were antagonized by the CB(1) antagonist rimonabant. Chronic Delta 9-THC (1 mg center dot kg-1 per 12 h, s.c.) resulted in tolerance to the rate-decreasing effects of Delta 9-THC and cross-tolerance to CP 55940 and WIN 55212-2; however, cross-tolerance was less than tolerance. Chronic Delta 9-THC increased sensitivity to rimonabant without changing sensitivity to the non-cannabinoids midazolam and ketamine. In monkeys discriminating Delta 9-THC (0.1 mg center dot kg-1, i.v.), both CP 55940 and WIN 55212-2 produced high levels of drug-lever responding. Chronic Delta 9-THC (1 mg center dot kg-1 per day, s.c.) decreased sensitivity to Delta 9-THC without producing cross-tolerance to CP 55940 or WIN 55212-2. CONCLUSIONS AND IMPLICATIONS In Delta 9-THC-treated monkeys, the magnitude of tolerance and cross-tolerance to other CB(1) receptor agonists varied inversely with agonist efficacy, suggesting that CB(1) agonist efficacy is an important determinant of behavioural effects.
引用
收藏
页码:1060 / 1073
页数:14
相关论文
共 50 条
  • [1] Tolerance and cross-tolerance produced by delta-9-tetrahydrocannabinol treatment in rhesus monkeys
    Hruba, Lenka
    Ginsburg, Brett C.
    McMahon, Lance R.
    [J]. FASEB JOURNAL, 2012, 26
  • [2] Apparent Inverse Relationship between Cannabinoid Agonist Efficacy and Tolerance/Cross-Tolerance Produced by Δ9-Tetrahydrocannabinol Treatment in Rhesus Monkeys
    Hruba, Lenka
    Ginsburg, Brett C.
    McMahon, Lance R.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 342 (03): : 843 - 849
  • [3] Rapid tolerance to Δ9-tetrahydrocannabinol and cross-tolerance between ethanol and Δ9-tetrahydrocannabinol in mice
    da Silva, GE
    Morato, GS
    Takahashi, RN
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 431 (02) : 201 - 207
  • [4] Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys
    Gerak, L. R.
    Zanettini, C.
    Koek, W.
    France, C. P.
    [J]. PSYCHOPHARMACOLOGY, 2015, 232 (19) : 3637 - 3647
  • [5] Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys
    L. R. Gerak
    C. Zanettini
    W. Koek
    C. P. France
    [J]. Psychopharmacology, 2015, 232 : 3637 - 3647
  • [6] Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments
    Wilkerson, Jenny L.
    Schulze, David R.
    Mcmahon, Lance R.
    [J]. PLOS ONE, 2019, 14 (03):
  • [7] Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal
    Gerak, L. R.
    France, C. P.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 357 (02): : 357 - 366
  • [8] ANANDAMIDES - TOLERANCE AND CROSS-TOLERANCE TO DELTA(9)-TETRAHYDROCANNABINOL
    FRIDE, E
    [J]. BRAIN RESEARCH, 1995, 697 (1-2) : 83 - 90
  • [9] Task specificity of cross-tolerance between Δ9-tetrahydrocannabinol and anandamide analogs in mice
    Wiley, JL
    Smith, FL
    Razdan, RK
    Dewey, WL
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 510 (1-2) : 59 - 68
  • [10] Rapid Nicotine Tolerance and Cross-Tolerance to Varenicline in Rhesus Monkeys: Drug Discrimination
    Moerke, Megan J.
    McMahon, Lance R.
    [J]. EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2018, 26 (06) : 541 - 548